Saturday, August 29, 2026
25.1
C
Bengaluru
Hot topics
Mounjaro Upends Semaglutide Gold Rush: IPM May 2026
1. The Eli Lilly & Mounjaro Disruption: A New...
Creador Bets Big on Indian Pharma with 7% La Renon Stake
In a significant development for the Indian pharmaceutical industry,...
Brecht Vanneste has been appointed as Managing Director of MSD India
He steps into the role with a clear mandate...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?
Something remarkable has happened in the Indian pharmaceutical market....
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?
Something remarkable has happened in the Indian pharmaceutical market....
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?
Something remarkable has happened in the Indian pharmaceutical market....
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?
Something remarkable has happened in the Indian pharmaceutical market....
Hot topics
Why Most AI Healthcare Tools Stall at the Pilot Stage
Artificial intelligence (AI) in healthcare consistently demonstrates remarkable technical...
Sun Pharma: In the Eye of the Storm of Ophthalmologists
The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...
7 Ways to Increase Productivity of Pharma Sales Reps
With access to HCPs becoming a daunting task for...
Customer Acquisition Cost (CAC) & Indian Pharma
Introduction
Customer Acquisition Cost (CAC) is a key metric representing...
Cipla–Pfizer Deal: How “Ordinary” Brands Are Fueling an Extraordinary Power Shift in Indian Pharma
What’s really happening in the Cipla–Pfizer tie‑up
At first glance,...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?
Something remarkable has happened in the Indian pharmaceutical market....
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?
Something remarkable has happened in the Indian pharmaceutical market....
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?
Something remarkable has happened in the Indian pharmaceutical market....
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?
Something remarkable has happened in the Indian pharmaceutical market....
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Newsletter
Get important news delivered directly to your inbox and stay connected!